RMC-4998 (formic)
RMC-4998 formic is an orally active inhibitor targeting the active or GTP-bound state of the KRASG12C mutant. RMC-4998 formic can form a ternary complex with intracellular CYPA and the activated KRASG12C mutant, with an IC50 value of 28 nM. RMC-4998 formic can inhibit ERK signaling in KRASG12C mutant cancer cells and induce apoptosis. RMC-4998 formic can be used for non-small cell lung cancer (NSCLC) research[1][2][3].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; ERK; mTOR; PI3K; Ras
Related Pathways
Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
99.02
Smiles
O=C(N1CCC[C@@H](C2=O)N1)[C@@H](NC([C@H](C(C)C)N3C([C@@]4(CCN(C(C#CC(C)(C)N(C)C)=O)C4)CC3)=O)=O)CC5=CC(C6=CC(C(CC(C)(C)CO2)=[C@@]([C@@]7=C([C@H](C)OC)N=CC=C7)N8CC)=C8C=C6)=CC=C5.OC=O
Molecular Formula
C58H76N8O9
Molecular Weight
1029.27
References & Citations
[1]Schulze CJ, et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science. 2023 Aug 18;381 (6659) :794-799.|[2]Kitai H, et al. Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer. Nat Commun. 2024 Jul 19;15 (1) :6076.|[3]Solanki H S, et al. RTK signaling and WT RAS activity as vulnerabilities in tumors with acquired resistance to GDP-state selective KRASG12C inhibitors in preclinical models[J]. Cancer Research, 2024, 84 (6_Supplement) : 1924-1924.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
RDR-SLC30A8-Hu-01 96 Tests
Human Solute Carrier Family 30 Member 8 (SLC30A8) ELISA Kit
Sign In for Pricing
View Details RDR-SLC30A8-Hu-02 48 Tests
Human Solute Carrier Family 30 Member 8 (SLC30A8) ELISA Kit
Sign In for Pricing
View Details 
